Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q3 2023 Earnings Presentation

43 slides from Day One Biopharmaceuticals's earnings presentation, Nov 6, 2023

  1. Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Targeted Therapies for People of All Ages November 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Drug Development For People Of All Ages

    Cancer Drug Development For People Of All Ages NDA data set included analysis of primary (ORR by RANO-HGG) and secondary (ORR by RAPNO-LGG, PFS) efficacy endpoints, safety, and exploratory analyses (including ORR by RANO-LGG). A Mission That Creates Value Develop medicines for genomically-defined ca

  4. Slide 4: Our Pipeline

    Our Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II RAF Inhibitor Relapsed pLGG Frontline pLGG Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors2 (Combo w/tovorafenib) VRK1 Program3 VRK1 Inhibitor Pediatric a

  5. Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor

    Tovorafenib (DAY101) Type II RAF Inhibitor

  6. Slide 6: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children

    Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children PLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term6 A Serious and Life-Threatening Disease Disease Symp

  7. Slide 7: Conventional Treatments Can Be Disruptive To Childhood

    Conventional Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences Significant recovery times Risks of complications Resection may be limited by location of tumor Potential for functional deficits based on location of tumor and extent of resection Risk of secondar

  8. Slide 8: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations Tovorafenib (DAY101) is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mu

  9. Slide 9: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects The Unrelenting Nature Of This Chronic Brain Tumor Because many pLGGs undergo senescence when patients reach their 20s, the goal of therapy is to maximize tumor control while minimizing treatment-associated toxicities from surgery, chemotherapy, and radia

  10. Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) – Fully Enrolled & Data Submitted to FDA Primary endpoint: ORR based on RANO-HGG1, assessed by blinded independent central review Secondary endpoints: ORR by RAPNO-LGG2 assessed by blinded independe

  11. Slide 11: Topline Data from Pivotal Phase FIREFLY-1 Trial

    Topline Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff

  12. Slide 12: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Characteristic Arm 1 (n=77) Median age, years (range) 8 (2-21) Sex, n (%) Male Female 40 (52) 37 (48) Race, n (%) Black or African American Asian White Multiple Other Not reported 2 (3) 5 (6) 41 (53) 3 (4) 6 (8) 20 (26) Number of lines of prior systemic the

  13. Slide 13: Topline Data From FIREFLY-1 Trial – June 5, 2023 Data Cutoff

    Topline Data From Ongoing, Fully Enrolled And NDA Submitted Pivotal Phase 2 FIREFLY-1 Trial – June 5, 2023 Data Cutoff June 5, 2023 data cutoff. RANO-HGG ORR (CR + PR). RAPNO-LGG & RANO-LGG ORR (CR + PR + MR), SPPD, Sum of Perpendicular Diameters. CBR, Clinical Benefit Rate (CR + PR + MR + SD). * In

  14. Slide 14: Tovorafenib Safety Data (n=137)

    Tovorafenib (DAY101) Safety Data (n=137) June 5, 2023 data cutoff. Safety data, based on the 137 patients treated in both Arm 1 and Arm 2 of FIREFLY-1, indicated monotherapy tovorafenib to be generally well-tolerated The vast majority of adverse events were Grade 1 or Grade 2, with most common treat

  15. Slide 15: Data from Pivotal Phase FIREFLY-1 Trial December 22, 2022 data cutoff

    Data from Pivotal Phase 2 FIREFLY-1 Trial December 22, 2022 data cutoff

  16. Slide 16: Tumor Response For Patients With RANO-HGG Evaluable Lesions

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=69) – December 22, 2022 Data Cutoff Response (IRC) RANO-HGG1 Evaluable n=69 ORR (cCR + cPR + uPR), n (%) 46 (67%)* Clinical benefit rate, n (%) cCR, cPR/uPR, or SD cCR, cPR/uPR, or SD for 12 mo+ 64 (93%) 49 (7

  17. Slide 17: Tumor Response For Patients With RAPNO-LGG Evaluable Lesions

    Tumor Response To Tovorafenib (DAY101) For All Patients With RAPNO-LGG Evaluable Lesions (n=69*) – December 22, 2022 Data Cutoff Response (IRC) RAPNO-LGG1 Evaluable n=69 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 35 (51%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD cCR, cPR/uPR, cMR/uMR, or

  18. Slide 18: Tumor Response For Patients With RANO-LGG Evaluable Lesions

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-LGG Evaluable Lesions (n=76) – December 22, 2022 Data Cutoff Response (IRC) RANO-LGG1 Evaluable n=76 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 37 (49%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD cCR, cPR/uPR, cMR/uMR, or SD

  19. Slide 19: Duration Of Tovorafenib Therapy For RANO-HGG & RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG & RANO-LGG Evaluable Lesions – December 22, 2022 Data Cutoff RANO-HGG (n=69) RANO-LGG (n=76) As of the data cutoff, the median IRC-assessed DOR based on RANO-LGG criteria was 14.4 months (95% CI: 8.4, not estimable)* As of the d

  20. Slide 20: Estimated BRAF-Altered pLGG Patient Population In The U.S.

    Estimated BRAF-Altered pLGG Patient Population In The U.S. 1 Selt F, van Tilburg CM, Bison B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020;149(3):499-510. doi:10.1007/s11060-020-03640-3. 2 Ryall S, Tabori U, Hawkins C. Pediatric low-g

  21. Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps

    Key Takeaways From FIREFLY-1 Data And Next Steps Next Steps Priority review granted with PDUFA target action date April 30, 2024 Clinically meaningful data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations (“BRAF-altered”) 67% ORR

  22. Slide 22: FIREFLY-2/LOGGIC Pivotal Phase Trial of Tovorafenib in Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG

  23. Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial Of Tovorafenib In Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG 1:1 Randomization Tovorafenib, 420mg/m2 QW (not to exceed 600 mg) Investigator's choice of vincristine/carboplatin* or vinblastine Long-term follow-up (48 months) Stratified by Location of tumor Genomic alteration CDKN2

  24. Slide 24: FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib With Pimasertib

    FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Combination with Pimasertib

  25. Slide 25: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clinical and clinical developmen

  26. Slide 26: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors Type II RAFi + MEKi is synergistic in BRAF fusion melanoma PDX model ex vivo (internal data) Sensitivity of KRAS Q61 mutant cells to pimasertib is enhanced when cells are tre

  27. Slide 27: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)

    Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) Pre-identified patients with advanced solid tumors and available clinical molecular profiling information. Phase 1b Tumors with MAPK pathway alterations *Additional biomarker-selected cohorts may be pursued based on developi

  28. Slide 28: Day One Biopharmaceuticals Summary

    Day One BIOPHARMACEUTICALS Summary

  29. Slide 29: Financial Summary: DAWN

    Financial Summary: DAWN $ Millions Nine Months Ended 9/30/23 Nine Months Ended 9/30/22 R&D Expense $93.2 $59.6 G&A Expense $53.4 $44.6 Net Loss $134.4 $102.1 Projected cash runway into 2026 FIREFLY-1: Pivotal Phase 2 clinical trial of tovorafenib (DAY101) Initiated rolling NDA1 in May 2023 Topline d

  30. Slide 30: Next Steps

    Next Steps FIREFLY-1 Initiated rolling NDA in May 2023 New topline data presented in September 2023 FDA acceptance of NDA and priority review granted in October 2023 PDUFA target action date of April 30, 2024 FIREFLY-2 Advance tovorafenib as a frontline therapy for patients with pLGG Currently activ

  31. Slide 31: Appendix

    Appendix

  32. Slide 32: Duration Of Tovorafenib Therapy For RANO-HGG Evaluable Lesions (n=69)

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions (n=69) 11/17 patients with stable disease <12 months remain on treatment as of data cutoff Partial response Complete response Progressive disease Discontinuation due to AE Death Ongoing treatment Discontinued t

  33. Slide 33: RANO-LGG Unconfirmed PR Patients Continue On Treatment With Deepening Of Response

    All RANO-LGG Unconfirmed PR Patients Continue On Treatment With Demonstrable Deepening Of Response (n=8) Responses for Patients with Unconfirmed Partial Response by RANO-LGG Percent Change from Baseline (%) Months from Baseline SD MR PR CR All 8 patients with unconfirmed partial response by RANO-LGG

  34. Slide 34: Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization

    Nearly Half Of Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization And Response With Continued Treatment (n=11) 5/11 patients with best response of PD by RANO-LGG remain on treatment as of May 23, 2023 Ongoing treatment Discontinued treatment Individual patient response data is cu

  35. Slide 35: Tovorafenib Safety Data (n=136)

    Tovorafenib (DAY101) Safety Data (n=136) Preferred term, n (%) Treatment-emergent AEs Treatment-related AEs Any grade Grade ≥3 Any grade Grade ≥3 Any AE 136 (100) 68 (50) 133 (98) 47 (35) Hair color changes 96 (71) - 96 (71) - Fatigue 68 (50) 4 (3) 54 (40) 4 (3) Vomiting 59 (43) 3 (2) 24 (18) 3 (2)

  36. Slide 36: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma

    Diagnostic biopsy Months A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma PR 1L: Vincristine/carboplatin Best respons

  37. Slide 37: Case Study: Tovorafenib In Posterior Fossa Pilocytic Astrocytoma

    Months An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma Suboccipital craniotomies 2L: Carboplatin/vincristine Best response PR PR 3L: Vi

  38. Slide 38: Case Study: Tovorafenib In BRAF V600E Deep Midline Astrocytoma

    Months A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty -60 Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma PR -48 -36 -24 -12 0 12 2L: Dabrafenib Best response PR 3L: Tovorafenib 1L: Carboplatin/vincristin

  39. Slide 39: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma Tumor kinetics Trametinib Tovorafenib Months -48 -36 -24 -12 0 12 -60 24 VC Binimetinib PR Initiated treatment with tovorafenib 400 mg/QW following 3 prior therapies, including binimetinib and trametinib, which

  40. Slide 40: FIREFLY-2/LOGGIC Pivotal Phase 3 Study In Newly Diagnosed pLGG

    Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research Coupled with the LOGGIC-CORE molecular diagnostic program Worked jointly on the study design and discussions with the U.S. and EU regulatory authorities FIREFLY-2/LOGGIC: Pivotal Phase 3 Stud

  41. Slide 41: Results From Independent Radiology Review Of PNOC014

    Results From Independent Radiology Review Of PNOC014 RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO-HGG: Response assessment for neuro-oncology-high grade glioma Volumetric image analysis (exploratory) Best response from baseline Date of data cutoff: 02 JAN 2020. Wright K

  42. Slide 42: Rapid, Deep And Durable Responses Following Tovorafenib Treatment In PNOC014

    Multiple Rapid, Deep And Durable Responses Observed Following Initiation Of Tovorafenib (DAY101) Treatment Of pLGG Patients In PNOC014 Growth kinetics of Target Lesions from Screening Date of data cutoff: 02 JAN 2020. Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020. Fangusaro J e

  43. Slide 43: Drug-related Adverse Events Observed for Tovorafenib in PNOC014

    Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Hypophosphatemia 4 (44%) Fatigue 5 (55%) Rash 8 (89%) Achromotrichia 7 (78%) Pruritis 6 (67%) Photosensitivity 1 (11%)

Day One Biopharmaceuticals — Q3 2023 Earnings Presentation on 6ix